Dermata Therapeutics Stock (NASDAQ:DRMA)
Previous Close
$1.43
52W Range
$1.29 - $17.85
50D Avg
$2.11
200D Avg
$5.45
Market Cap
$2.08M
Avg Vol (3M)
$2.22M
Beta
0.77
Div Yield
-
DRMA Company Profile
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.
DRMA Performance
Peer Comparison
Ticker | Company |
---|---|
ZVSA | ZyVersa Therapeutics, Inc. |
ENSC | Ensysce Biosciences, Inc. |
PHIO | Phio Pharmaceuticals Corp. |
REVB | Revelation Biosciences, Inc. |
AVRO | AVROBIO, Inc. |
EFTR | eFFECTOR Therapeutics, Inc. |
IMMX | Immix Biopharma, Inc. |
CYTO | Altamira Therapeutics Ltd. |
SONN | Sonnet BioTherapeutics Holdings, Inc. |
WINT | Windtree Therapeutics, Inc. |
HEPA | Hepion Pharmaceuticals, Inc. |
BXRX | Baudax Bio, Inc. |
ZURA | Zura Bio Limited |
CDIO | Cardio Diagnostics Holdings, Inc. |
ATNF | 180 Life Sciences Corp. |